Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
C647428-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $130.90 | |
C647428-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $270.90 | |
C647428-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $420.90 | |
C647428-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $840.90 | |
C647428-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,200.90 |
Specifications & Purity | ≥98% |
---|---|
Biochemical and Physiological Mechanisms | CSF1R-IN-1 is a CSF1R inhibitor with an with an IC 50 of 0.5 nM. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Product Description | CSF1R-IN-1 is a CSF1R inhibitor with an with an IC 50 of 0.5 nM. In Vitro CSF1R is thought to play an important role in recruitment and differentiation of tumor-associated macrophages (TAMs). CSF1R-IN-1 (compound 22) shows good intestinal permeability in a Caco2 assay. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo CSF1R-IN-1 has favorable pharmacokinetics when dosed orally to mice. It appears suitable for in vivo pharmacology testing in the appropriate preclinical tumor model to demonstrate proof of concept. . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male CD-1 mice, 25-35 grams (8-11 weeks old) Dosage: 2 mg/kg IV or 10 mg/kg orally (Per Os) Administration: i.v. or oral Result: I.V.: C max =3.55, T 1/2 =0.87\nP.O.: C max =4.6, T 1/2 =1.8, Bioavailability=64% Form:Solid IC50& Target:IC50: 0.5 nM (CSF1R) |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 5-(1-methylpyrazol-4-yl)-N-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]pyridine-3-carboxamide |
---|---|
INCHI | InChI=1S/C25H20F3N5O2/c1-15-6-7-21(31-23(34)16-4-3-5-20(9-16)25(26,27)28)10-22(15)32-24(35)18-8-17(11-29-12-18)19-13-30-33(2)14-19/h3-14H,1-2H3,(H,31,34)(H,32,35) |
InChi Key | BMEXIUCHJUGPRB-UHFFFAOYSA-N |
Canonical SMILES | CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(F)(F)F)NC(=O)C3=CN=CC(=C3)C4=CN(N=C4)C |
Isomeric SMILES | CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(F)(F)F)NC(=O)C3=CN=CC(=C3)C4=CN(N=C4)C |
PubChem CID | 137333440 |
Molecular Weight | 479.5 |
Enter Lot Number to search for COA:
Solubility | DMSO : 83.33 mg/mL (173.80 mM; Need ultrasonic) |
---|